Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722547 | 1.00 | AKR1C1 (0.57) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| Hydrochloric Acid SCHEMBL1804765 | 0.98 | AKR1C1 (0.55) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL42114 | 0.91 | AKR1C1 (0.70) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL2184245 | 0.91 | AKR1C1 (0.64) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL43810 | 0.90 | AKR1C1 (0.68) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL30662077 | 0.88 | AKR1C1 (0.46) | AKR1C1HSD11B1OPRL1HDAC1 | |
| SCHEMBL2703559 | 0.86 | ALDH1A1 (0.58) | AKR1C1OPRL1HDAC1SMN1; SMN2CYP2C9 | |
| SCHEMBL8366154 | 0.86 | OPRL1 (0.56) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL476403 | 0.86 | OPRM1 (0.58) | AKR1C1HSD11B1OPRL1HDAC4HDAC1 | |
| SCHEMBL7864618 | 0.86 | AKR1C1 (0.48) | AKR1C1HSD11B1OPRL1HDAC4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| CN-115584014-A | Ladder-shaped polymer material with heat-resisting and fluorescent characteristics and preparation method thereof | 大连理工大学 | 2023-01-10 | — | — | CN | claimed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2021-03-18 | — | — | US | claimed |
| EP-3759114-A1 | HETEROBICYCLIC CARBOXYLIC ACIDS AND SALTS THEREOF | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2021-01-06 | — | — | EP | claimed |
| EP-3749323-A1 | HETEROBICYCLIC CARBOXYLIC ACIDS FOR TREATING CANCER OR INFLAMMATORY DISEASES | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2020-12-16 | — | — | EP | claimed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | claimed |
| CN-111936502-A | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2020-11-13 | — | — | CN | claimed |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2020-11-12 | — | — | US | claimed |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2006-07-06 | — | — | US | claimed |
| EP-1599476-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-30 | — | — | EP | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | claimed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | claimed |
| WO-2004076453-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-09-10 | — | — | WO | claimed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | claimed |
| JP-2002541138-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | PTGER4, PTGER1, GPR4 | AKR1C1 1101/4885HSD11B1 770/4885OPRL1 67/4885 |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | CHRNA6, CHRNA10, CHRNA2 | AKR1C1 1515/4885HSD11B1 1556/4885OPRL1 20/4885 |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | MAP3K19, MAP3K1, MAP3K3 | AKR1C1 1337/4885HSD11B1 1924/4885OPRL1 4481/4885 |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | PTGER4, PTGER1, PTGER2 | AKR1C1 1014/4885HSD11B1 609/4885OPRL1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.